Long-Term Outcomes of Tisagenleucel in Pediatric Acute Lymphoblastic Leukemia

Tisagenleucel (Kymriah), a chimeric antigen receptor (CAR) T-cell therapy, provides durable remission for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL). Long-term data from clinical trials, including the pivotal ELIANA study, demonstrate that patients who achieve minimal residual disease (MRD) negativity post-infusion often maintain disease-free survival for years, signaling a meaningful shift in treating high-risk pediatric malignancies.

What is Tisagenleucel and How Does It Work?

Tisagenleucel is a personalized immunotherapy that modifies a patient’s own T-cells to recognize and eliminate cancer cells. According to the U.S. Food and Drug Administration (FDA), the process involves collecting T-cells via apheresis, genetically engineering them to express a CAR that targets the CD19 antigen found on B-cells, and re-infusing them into the patient. Once inside the body, these cells multiply and attack the leukemia. The National Cancer Institute notes that this “living drug” approach differs significantly from chemotherapy, as the cells can persist in the bloodstream, providing long-term surveillance against the cancer.

What Do Long-Term Survival Figures Show?

Research published in the Journal of Clinical Oncology highlights the durability of responses in pediatric patients. In the ELIANA trial, five-year follow-up data showed that the probability of relapse-free survival was 44% among patients who achieved a complete response. Dr. Shannon Maude, a lead researcher at the Children’s Hospital of Philadelphia, has noted that for patients who achieve MRD negativity—a state where no leukemia cells are detectable via sensitive molecular testing—the outcomes are particularly favorable. While chemotherapy historically offered low cure rates for patients who had already failed multiple lines of treatment, CAR T-cell therapy provides a bridge to long-term survival for many in this high-risk group.

How Does CAR T-Cell Therapy Compare to Traditional Options?

The efficacy of tisagenleucel is often evaluated against traditional salvage chemotherapy or hematopoietic stem cell transplantation (HSCT). The following table summarizes the clinical focus of these approaches:

What Are the Risks and Side Effects?

While effective, tisagenleucel carries significant clinical risks that require specialized care. The Novartis prescribing information warns of cytokine release syndrome (CRS), a systemic inflammatory response caused by the rapid activation of T-cells. Symptoms can range from high fever and hypotension to multi-organ failure. Neurological toxicities, known as immune effector cell-associated neurotoxicity syndrome (ICANS), also occur in a subset of patients. Because of these risks, the FDA mandates that centers administering the therapy be certified in a Risk Evaluation and Mitigation Strategy (REMS) program to manage these complex side effects.

What Happens After Infusion?

Post-infusion care focuses on monitoring for both leukemia recurrence and B-cell aplasia—a side effect where the therapy continues to eliminate healthy B-cells, which are also CD19 positive. According to the Children’s Hospital of Philadelphia, patients often receive immunoglobulin replacement therapy to compensate for the loss of B-cells, which produce antibodies. Ongoing research is currently exploring how to improve the persistence of CAR T-cells in patients who lose their response and how to better manage the long-term immunological consequences of this therapy.